oncology
-
Liminatus Pharma to acquire InnocsAI in US$320M share-based CAR-T oncology deal
Liminatus went public in 2022 through a SPAC merger and initially highlighted several immune-modulating therapies originating from research collaborations in the United States and South Korea.
-
JOOTRH’s Comprehensive Cancer Centre set to begin radiotherapy services this year as data reveals growing crisis
The new comprehensive center will change this reality by providing chemotherapy, radiotherapy, and surgical oncology services under one roof.
-
Johnson & Johnson expands oncology portfolio with USD3B acquisition of Halda Therapeutics
Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.
-
Mubadala Bio’s Bioventure Healthcare opens high-capacity facility for oncology products
The newly constructed, purpose-built facility is designed to handle high potency drugs, including oncology and hormone products.
-
Genmab halts phase 1/2 trial for oncology candidate GEN1160 amid broader strategic review
GEN1160 now joins GEN1107 on Genmab’s list of discontinued assets from the April 2024 ProfoundBio acquisition.
-
Moderna axes three clinical-stage mRNA candidates to focus R&D on oncology
A company spokesperson explained that Moderna has “prioritized our pipeline and R&D investments as part of our broader cost efficiency efforts,” though the company provided no additional details about the specific discontinuations.